Neural progenitor cells - potent models of normal and disease neurobiology

Brian Shapiro, Ph.D.

Technical Writer, Cell Biology, ATCC

November 19, 2015






About ATCC

- Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas, VA
- World's premiere biological materials resource and standards development organization
- ATCC collaborates with, and supports, the scientific community with industry-standard biological products and innovative solutions
- Strong team of 400+ employees; over onethird with advanced degrees





ATCC neuroscience cell lines




ATCC

Stanford Medicine, 2009

3

ATCC neuroscience cell lines



Stanford Medicine, 2009

ATCC




Introduction

- Neural differentiation
- Neural progenitor cells (NPCs)

Expanding and differentiating neural progenitors


- Fibroblast- and CD34⁺-derived NPCs
- Lineage-specific GFP or NanoLuc[®]-HaloTag[®] reporter NPCs
- The advantages of our complete NPC system

ATCC NPC availability and summary





Why use NPCs?



Neural progenitor cells

Human NPCs are widely used:


- Drug discovery
- Toxicological assessment
- Preclinical studies

Advantages of using NPCs:

- Human models with no donor variation
 - Biologically relevant results/predictive system
- Cells exhibit full differentiation spectrum
 - Neurons
 - Astrocytes
 - Oligodendrocytes
- Easy to use
 - Complete system of cells and media will be available
 - Live imaging is possible
 - Markers allow for easy endpoint readout
- Saves time



iPSCs for generating NPCs






7




	ATCC [®] No.	Designation	Gender	Ethnicity
· All Maria	ACS-1024™	ATCC-BYS0110	Male	African American
1 Children Children	ACS-1028™	ATCC-BYS0114	Female	African American
	ACS-1025™	ATCC-BYS0111	Male	Hispanic
	ACS-1029™	ATCC-BXS0115	Female	Hispanic
	ACS-1026™	ATCC-BYS0112	Male	Caucasian
	ACS-1030™	ATCC-BXS0116	Female	Caucasian
	ACS-1027™	ATCC-BYS0113	Male	Asian
	ACS-1031™	ATCC-BXS0117	Female	Asian

Neuronal differentiation of iPSCs



iPSC-derived NPCs are useful for disease modeling


- Wren and colleagues created iPSCs from microtubule-associated protein tau (MAPT) N279K Parkinson's disease patients
- NPCs were created
- N279K causes increases in 4 repeat to 3 repeat tau domains in MAPT
- Since MAPT binds microtubules vesicle trafficking was investigated
- NPCs derived from patients with mutation displayed impaired endocytic trafficking





NPCs for toxicological studies

- NPCs can be used to develop high throughput toxicological studies
- Embryonic mouse brains NPCs were isolated and differentiated
- Calcium ion flux
- Multi-electrode array experiments
- Cells were sensitive to neurotransmitters
 - Acetylcholine
 - Dopamine
 - Serotonin
 - GABA





Overview


Introduction

- Neural differentiation
- Neural progenitor cells (NPCs)

Expanding and differentiating neural progenitors

- Fibroblast- and CD34⁺-derived NPCs
- Lineage-specific GFP or NanoLuc[®]-HaloTag[®] Reporter NPCs
- The advantages of our complete NPC system

ATCC NPC availability and summary





QC testing of ATCC[®] NPCs


- Post-thaw cell viability: >80%
- Post-thaw viable cell number: >1x10⁶ cells/vial
- Longevity: >15 PDLs or 5 passages
- NPC marker expression: Nestin⁺, Pax-6⁺, and Tra-I-60⁻
- Differentiation potential:


>70% Tuj1⁺ early neurons and >10% TH⁺ dopaminergic neurons

- Identity: STR profile matching parental iPSC line
- Sterility, Mycoplasma, and viral panel testing: None detected



Morphology and growth curves of NPCs derived from CD34⁺, HFF-1, and Parkinson's iPSC lines






- NPCs derived from foreskin fibroblasts and CD34+ demonstrated greater proliferative capacity than Parkinson's disease
- CD34⁺-derived NPCs exhibited better morphology than the other types




NPCs derived from CD34+, HFF-1, and Parkinson's iPSC lines expressed Nestin and Pax-6 NPC markers





Dopaminergic neuron differentiation of NPCs













Astrocyte and oligodendrocyte differentiation of **NPCs**

Astrocyte differentiation





Oligodendrocyte differentiation








Parkinson's




NPC Reporter lines and constructs

DCXp-GFP: Mature neuron reporter line


ATCC [®] No.	Designation		
ACS-5005™	DCXp-GFP Neural Progenitor Cells, Human, Normal Origin: XCL-1 hiPSCs		
ACS-5006™	GFAP-Nanoluc-Halotag Neural Progenitor Cells, Human, Normal Origin: XCL-1 hiPSCs		
ACS-5007™	MAP2-Nanoluc-Halotag Neural Progenitor Cells, Human, Normal Origin: XCL-1 hiPSCs		



GFAP-Nanoluc-Halotag: Astrocyte reporter line



MAP2-Nanoluc-Halotag: Early neuron reporter line



18




NPC marker expression in reporter NPC lines

DCXp-GFP


GFAP-Nanoluc-Halotag

MAP2-Nanoluc-Halotag





Dopaminergic neuron differentiation of NPC reporter lines



MAP2-Nanoluc-Halotag


DCXp-GFP


GFAP-Nanoluc-Halotag



Expression of the luciferase reporter during dopaminergic neuron or astrocyte differentiation


Luciferase secretion during dopaminergic neuron differentiation of MAP2-Nanoluc-Halotag NPCs






Luciferase secretion during astrocyte differentiation of GFAP-Nanoluc-Halotag NPCs








Expression of the GFP or Halotag reporter during dopaminergic neuron or astrocyte differentiation




ATCC

22

Development of ATCC NPC growth media




Marker expression and astrocyte differentiation of NPCs cultured in ATCC growth media





Development of ATCC dopaminergic neuron differentiation media (ATCC[®] ACS-3004[™])






Overview

Introduction

- Neural differentiation
- Neural progenitor cells (NPCs)
- Expanding and differentiating neural progenitors
 - Fibroblast- and CD34⁺-derived NPCs
 - Lineage-specific GFP or NanoLuc[®]-HaloTag[®] Reporter NPCs
 - The advantages of our complete NPC system

ATCC NPC availability and summary






ATCC initial NPC offerings

ATCC [®] No.	Designation	Availability
ACS-3003™	Neural Progenitor Cell Growth Kit	Late 2015
ACS-3004™	Dopaminergic Differentiation Kit	Late 2015
ACS-5001™	Neural Progenitor Cells, Parkinson's Origin: ATCC-DYS0530 (ACS-1013™) hiPSCs	In development
ACS-5003™	Neural Progenitor Cells, Normal Origin: ATCC-BXS0117 (ACS-1031™) hiPSCs	Late 2015
ACS-5004™	Neural Progenitor Cells, Normal Origin: ATCC-BYS0112 (ACS-1026™) hiPSCs	Late 2015
ACS-5005™	DCXp-GFP Neural Progenitor Cells, Normal Origin: XCL-1 hiPSCs	Late 2015
ACS-5006™	GFAP-Nanoluc-Halotag Neural Progenitor Cells, Normal Origin: XCL-1 hiPSCs	Late 2015
ACS-5007™	MAP2-Nanoluc-Halotag Neural Progenitor Cells, Normal Origin: XCL-1 hiPSCs	Late 2015




Summary

- Developed a process enabling generation of unlimited supply of neural progenitor cells
- Optimized culture conditions for the expansion and tri-lineage differentiation of NPCs
- Starting iPSC lines played an important role in morphology, proliferative capacity, and differentiation potential of NPCs
- CD34⁺-derived NPCs exhibited a better proliferative capacity and greater efficiency of tri-lineage differentiation
- Three gene-edited NPC reporter lines expressed GFP, NanoLuc[®], or HaloTag[®] during lineage specific differentiation
- ATCC complete solution of NPC products including NPCs and culture media provides a powerful tool for disease modeling and drug screening





Acknowledgments



Project team: Leelamma Jacob, M.S., Ph.D. Michelle Spencer, M.S. Dezhong Yin, Ph.D.

Trademarks

NanoLuc[®]-HaloTag[®] are registered trademarks of the Promega Corporation





Thank you

Questions?

